Rwanda has become the third country to sign a memorandum of understanding with Novartis Access after Kenya and Ethiopia, which will help the Rwandan government to increase investment in prevention, diagnosis and treatment of chronic diseases (NCDs).
Chronic diseases like high blood pressure and diabetes impact more than just wealthy nations. Novartis Foundation and Novartis Access works to address the rising threat of chronic diseases in developing countries by improving access to healthcare.
P5 members include NIAID, the Bill & Melinda Gates Foundation, the South African Medical Research Council, HVTN, Sanofi Pasteur, GSK and the U.S. Military HIV Research Program.
EOS imaging announced the recent entry into the North African market with the opening of two EOS sites in Tunisia.
Novartis has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries.
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
When HIV-positive patients first came to seek treatment at the rural Uthungulu district health clinic in South Africa’s eastern KwaZulu-Natal province in 1998, their records were kept in brown folders, the colour designated for the disease.